Brief: Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c

Corcept Therapeutics Incorporated

23/06/2025 21:58

June 23 (Reuters) - Corcept Therapeutics Inc CORT.O:

CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARE

CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1C

CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE

Source text: ID:nBw7PP9vfa

Further company coverage: CORT.O

 ((Reuters.Briefs@thomsonreuters.com;))